Literature DB >> 15662115

Effects of HIV-1 Nef, a cytotoxic viral protein, on the growth of primary colorectal cancer.

Harvey L Bumpers1, Ming-Bo Huang, Michael Powell, William E Grizzle, James W Lillard, Joel Okoli, Vincent C Bond.   

Abstract

Colorectal cancer is the third leading cause of cancer deaths in American men and women. We describe the cytotoxic use of HIV-1 Nef protein and a cytotoxic peptide identified within the HIV-1 Nef structure in targeting human cancer cells in vitro and in vivo in a human xenograft model. A human colorectal tumor was implanted and propagated in the subcutaneous tissue of SCID mice. The mice were injected biweekly with the Nef apoptotic peptide. The tumor treated with Nef peptide underwent significant growth inhibition by as much as 300 percent when compared to the control (untreated) tumors. The Nef peptides were found to have an apoptotic effect on the human colon tumor similar to the effect seen on CD4 cells when the viral protein is secreted by the HIV-1 virus infected cells. The evidence from the xenograft mouse model suggests that the Nef peptides can be used to inhibit human colorectal cancer growth.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15662115     DOI: 10.4161/cbt.4.1.1377

Source DB:  PubMed          Journal:  Cancer Biol Ther        ISSN: 1538-4047            Impact factor:   4.742


  7 in total

1.  HIV Nef-M1 Effects on Colorectal Cancer Growth in Tumor-induced Spleens and Hepatic Metastasis.

Authors:  Willie Harrington; Vincent Bond; Ming Bo Huang; Michael Powell; James Lillard; Upender Manne; Harvey Bumpers
Journal:  Mol Cell Pharmacol       Date:  2009-08-05

2.  Paracrine modulation of CXCR4 by IGF-1 and VEGF: implications for choroidal neovascularization.

Authors:  Nilanjana Sengupta; Aqeela Afzal; Sergio Caballero; Kyung-Hee Chang; Lynn C Shaw; Ji-Jing Pang; Vincent C Bond; Imran Bhutto; Takayuki Baba; Gerard A Lutty; Maria B Grant
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-12-10       Impact factor: 4.799

3.  Nef-M1, a peptide antagonist of CXCR4, inhibits tumor angiogenesis and epithelial‑to‑mesenchymal transition in colon and breast cancers.

Authors:  Venkat R Katkoori; Marc D Basson; Vincent C Bond; Upender Manne; Harvey L Bumpers
Journal:  Oncotarget       Date:  2015-09-29

Review 4.  Inhibition of CXCL12/CXCR4 axis as a potential targeted therapy of advanced gastric carcinoma.

Authors:  Li-Jun Xue; Xiao-Bei Mao; Li-Li Ren; Xiao-Yuan Chu
Journal:  Cancer Med       Date:  2017-05-23       Impact factor: 4.452

5.  Secretion modification region-derived peptide blocks exosome release and mediates cell cycle arrest in breast cancer cells.

Authors:  Ming-Bo Huang; Ruben R Gonzalez; James Lillard; Vincent C Bond
Journal:  Oncotarget       Date:  2017-02-14

6.  Small molecule CXCR4 antagonists block the HIV-1 Nef/CXCR4 axis and selectively initiate the apoptotic program in breast cancer cells.

Authors:  Ming-Bo Huang; Kyle E Giesler; Brooke M Katzman; Anthony R Prosser; Valarie Truax; Dennis C Liotta; Lawrence J Wilson; Vincent C Bond
Journal:  Oncotarget       Date:  2018-02-26

7.  Nef-M1, a CXCR4 Peptide Antagonist, Enhances Apoptosis and Inhibits Primary Tumor Growth and Metastasis in Breast Cancer.

Authors:  Harvey Bumpers; Ming-Bo Huang; Venkat Katkoori; Upender Manne; Vincent Bond
Journal:  J Cancer Ther       Date:  2013-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.